Gemfibrozil--a new lipid lowering agent.
Thirty patients with type II and IV hyperlidemia were studied by a double blind cross over technic. Gemfibrozil at dosages of 1200 mg and 1600 mg a day was compared to 2000 mg daily of clofibrate. The effect of each drug regimen is described for the entire study population and for those who were found to be responders.
D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D015248:Gemfibrozil; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000188:drug therapy*; D006953:Hyperlipoproteinemia Type IV / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D010421:Pentanoic Acids / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood; D014631:Valerates / Q000627:therapeutic use*; D014992:Xylenes / Q000627:therapeutic use
D000960:Hypolipidemic Agents; D010421:Pentanoic Acids; D014280:Triglycerides; D014631:Valerates; D014992:Xylenes; D002784:Cholesterol; D002994:Clofibrate; D015248:Gemfibrozil